海外の治験の状況「前立腺癌」での検索結果
161件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Recruiting
- A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Austria, Belgium, France, Germany, Israel, Luxembourg, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom
- 2015-10-28
Authorised
- Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
- Metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Brazil, Canada, China, Denmark, France, Germany, Israel, Japan, Korea, Republic of, Netherlands, Norway, Spain, Sweden, Taiwan, United Kingdom, United States
- 2017-01-03
Authorised
- An international study to evaluate the effectiveness of Talazoparib in men with a genomic defect and metastatic castration-resistant prostate cancer who received previous chemotherapy and progressed on hormonal treatment
- Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone) MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Spain, United Kingdom, United States
- 2016-09-15
Recruiting
- A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
- Prostate Cancer
- Australia, Austria, Belgium, Brazil, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Spain, United Kingdom, United States
- 2017-05-09
Not recruiting
- A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
- Prostate Cancer
- Argentina, Australia, Austria, Belgium, Brazil, Chile, China, Czechia, France, Germany, Hong Kong, Israel, Italy, Mexico, New Zealand, Poland, Romania, Russian Federation, Singapore, Spain, Turkey, United Kingdom, United States
- 2019-09-20
Not Recruiting
- Improvement of detection of clinically significant prostate cancer by combination of molecular urine markers and multiparametric MRI of the prostate
- ;C61 - Malignant neoplasm of prostate
- Austria, Germany
- 2019-12-30
Not recruiting
- A randomised trial investigating the effectiveness of different durations of maximal androgen deprivation prior to and during definitive radiation therapy for locally advanced carcinoma of the prostate
- Prostate Cancer
- Australia, New Zealand
- 1995-12-18
Not recruiting
- A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
- Cancer, Prostate;Cancer, Prostate;Cancer, Prostate;Cancer, Prostate
- Austria, Belgium, France, Germany, Spain, United Kingdom, United States
- 2006-10-06
Not recruiting
- A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
- Prostate Cancer
- Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States
- 2002-05-10
Not recruiting
- Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
- Prostatic Neoplasms
- Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, United Kingdom, United States
- 2002-05-10